Indication intelligence, analysis and sector perception

Fate Therapeutics (FATE) priced their 9,250,260 share offering at $13.50 for an aggregate of approximately $125 million

September 21, 2018 8:13am

FATE had closed at $14.03 (+$0.67 or +5.01%) and was down in the pre-market -$0.63 or -4.49%

FATE had 53.42 M shares outstanding, a float of 44.68 M and a 52 week change of +224.27% with a cash position of $78.02 M and $14.85 M in debt on the books

A good move after a market high and collaboration news with ONO Pharmaceuticals

FATE priced an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, for an aggregate offering of approximately $125.0 million.

FATE has granted the underwriters a 30-day option to purchase up to an additional 1,388,889 shares of its common stock.

The proceeds to FATE from this offering are expected to be approximately $117.2 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters’ option.

Jefferies, Piper Jaffray, and Wells Fargo Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as a co-manager for the offering.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 7 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.